Michael John Aldape1, Dustin Delaney Heeney2, Amy Evelyn Bryant3, Dennis Leroy Stevens3. 1. Department of Veterans Affairs Medical Center, 500 W. Fort Street, Boise, ID 83702, USA mike.aldape@va.gov. 2. Department of Veterans Affairs Medical Center, 500 W. Fort Street, Boise, ID 83702, USA. 3. Department of Veterans Affairs Medical Center, 500 W. Fort Street, Boise, ID 83702, USA University of Washington School of Medicine, 1959 NE Pacific Street, Seattle, WA 98195, USA.
Abstract
BACKGROUND: Clostridium difficile infection (CDI) is mediated by potent extracellular toxins and is spread largely via bacterial spores. We and others have shown that some antibiotics stimulate C. difficile toxin production in a strain-specific manner; however, the effects of newer anti-C. difficile antibiotics on this process remain to be investigated. METHODS: The effects of the protein synthesis inhibitor tigecycline on sporulation and toxin A and toxin B production were compared in historical (strain 9689) and hypervirulent BI/NAP1/027 (strain 5325) isolates of C. difficile in vitro. RESULTS: Tigecycline at 1/4× MIC stimulated an increased and earlier toxin A and/or B gene expression in both the historical and the hypervirulent strains, although a commensurate increase in toxin protein production was observed only in the 9689 strain. In fact, in the hypervirulent 5325 strain, toxin production was dramatically suppressed. By comparison, subinhibitory concentrations of vancomycin and metronidazole also stimulated increased protein toxin production by the historical, but not the hypervirulent, strain. In addition, tigecycline dose-dependently reduced viable spore production by both the 9689 and 5325 strains. Vancomycin treatment also suppressed spore formation in both C. difficile strains; however, metronidazole, while reducing spore formation in the 9689 strain, stimulated a near 2 log increase in spore production by the 5325 isolate. CONCLUSIONS: In summary, these findings suggest that the treatment of CDI patients with tigecycline could effectively both control disease progression and limit its spread by disrupting sporulation.
BACKGROUND:Clostridium difficileinfection (CDI) is mediated by potent extracellular toxins and is spread largely via bacterial spores. We and others have shown that some antibiotics stimulate C. difficile toxin production in a strain-specific manner; however, the effects of newer anti-C. difficile antibiotics on this process remain to be investigated. METHODS: The effects of the protein synthesis inhibitor tigecycline on sporulation and toxin A and toxin B production were compared in historical (strain 9689) and hypervirulent BI/NAP1/027 (strain 5325) isolates of C. difficile in vitro. RESULTS:Tigecycline at 1/4× MIC stimulated an increased and earlier toxin A and/or B gene expression in both the historical and the hypervirulent strains, although a commensurate increase in toxin protein production was observed only in the 9689 strain. In fact, in the hypervirulent 5325 strain, toxin production was dramatically suppressed. By comparison, subinhibitory concentrations of vancomycin and metronidazole also stimulated increased protein toxin production by the historical, but not the hypervirulent, strain. In addition, tigecycline dose-dependently reduced viable spore production by both the 9689 and 5325 strains. Vancomycin treatment also suppressed spore formation in both C. difficile strains; however, metronidazole, while reducing spore formation in the 9689 strain, stimulated a near 2 log increase in spore production by the 5325 isolate. CONCLUSIONS: In summary, these findings suggest that the treatment of CDIpatients with tigecycline could effectively both control disease progression and limit its spread by disrupting sporulation.
Authors: Dhara Shah; Minh-Duc Dang; Rodrigo Hasbun; Hoonmo L Koo; Zhi-Dong Jiang; Herbert L DuPont; Kevin W Garey Journal: Expert Rev Anti Infect Ther Date: 2010-05 Impact factor: 5.091
Authors: P Kopterides; C Papageorgiou; A Antoniadou; E Papadomichelakis; I Tsangaris; I Dimopoulou; A Armaganidis Journal: Anaesth Intensive Care Date: 2010-07 Impact factor: 1.669
Authors: Matthew Hoffmann; William DeMaio; Ronald A Jordan; Rasmy Talaat; Dawn Harper; John Speth; JoAnn Scatina Journal: Drug Metab Dispos Date: 2007-05-30 Impact factor: 3.922
Authors: Trevor D Lawley; Nicholas J Croucher; Lu Yu; Simon Clare; Mohammed Sebaihia; David Goulding; Derek J Pickard; Julian Parkhill; Jyoti Choudhary; Gordon Dougan Journal: J Bacteriol Date: 2009-06-19 Impact factor: 3.490
Authors: Casey M Theriot; Cassie A Schumacher; Christine M Bassis; Anna M Seekatz; Vincent B Young Journal: Antimicrob Agents Chemother Date: 2014-12-29 Impact factor: 5.191
Authors: Mary T LaSalvia; Westyn Branch-Elliman; Graham M Snyder; Monica V Mahoney; Carolyn D Alonso; Howard S Gold; Sharon B Wright Journal: Open Forum Infect Dis Date: 2017-02-10 Impact factor: 3.835
Authors: Ewelina Piktel; Katarzyna Pogoda; Maciej Roman; Katarzyna Niemirowicz; Grażyna Tokajuk; Marta Wróblewska; Beata Szynaka; Wojciech M Kwiatek; Paul B Savage; Robert Bucki Journal: Sci Rep Date: 2017-03-15 Impact factor: 4.379
Authors: Jiqing Ye; Adrian Jun Chu; Lin Lin; Shu Ting Chan; Rachel Harper; Min Xiao; Irina Artsimovitch; Zhong Zuo; Cong Ma; Xiao Yang Journal: Eur J Med Chem Date: 2020-08-18 Impact factor: 6.514